CD274 and non-small cell lung carcinoma: Although the recent therapeutic advances have provided significant survival benefits of some selected patients with non-small cell lung cancer (NSCLC), approximately 60% NSCLC do not have targetable driver mutations, and only 20% NSCLC patients might respond to anti-PD-1 or PD-L1 treatment [1–3].